To hear about similar clinical trials, please enter your email below
Trial Title:
Triple BRAFinh/MEKinh /antiPD1 Combined Therapy in Patients With BRAF Mutated Melanoma With Central Nervous System Metastasis
NCT ID:
NCT05510466
Condition:
Metastatic Melanoma
Conditions: Official terms:
Melanoma
Neoplasm Metastasis
Conditions: Keywords:
Initially treated by a doubled targeted therapy anti BRAF/anti MEK
immunotherapy
combined tritherapy
melanoma's brain metastasis
With an intra cerebral progression of the tumor
Study type:
Observational
Overall status:
Unknown status
Study design:
Time perspective:
Retrospective
Summary:
Currently, therapeutic options in BRAF mutated melanoma with brain metastasis occurring
after achievement of a good control of extracerebral secondary lesions by a first line
combined targeted therapy (TT) are limited. In this setting, the addition of an anti PD1
agent to TT may be proposed as a second line strategy. This observational survey aims at
investigating the benefit/risk ratio of this triple combination in a small cohort of
patients.
Criteria for eligibility:
Study pop:
- Metastatic melanoma BRAF mutated
- Initially treated by a doubled targeted therapy anti BRAF/anti MEK
- With an intra cerebral progression of the tumor
- Whom we add an check point inhibitor anti PD1, combined with the double targeted
therapy
- between 01/2019 et 01/2022
Sampling method:
Non-Probability Sample
Criteria:
Inclusion criteria:
- Metastatic melanoma BRAF mutated
- Initially treated by a doubled targeted therapy anti BRAF/anti MEK
- With an intra cerebral progression of the tumor
- Whom we add an check point inhibitor anti PD1, combined with the double targeted
therapy
- between 01/2019 et 01/2022
Exclusion criteria:
- Other condition
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Uhmontpellier
Address:
City:
Montpellier
Zip:
34295
Country:
France
Status:
Recruiting
Contact:
Last name:
Olivier DEREURE, MD, PhD
Phone:
467336906
Phone ext:
33
Email:
o-dereure@chu-montpellier.fr
Start date:
January 1, 2019
Completion date:
March 1, 2023
Lead sponsor:
Agency:
University Hospital, Montpellier
Agency class:
Other
Source:
University Hospital, Montpellier
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05510466
